RATIONALE: Low dose oral immunotherapy (OIT), which maintenance doses are lower than threshold doses diagnosed by oral food challenges (OFCs), is not evaluated the safety and efficacy. METHODS: This was a retrospective case series study, evaluating patients who 1) tested positive on open OFCs with <10 g or ml of boiled egg white or milk from June 2016 to March 2017; 2) consumed the causative foods for one year as OIT, initiated at 1/100-1/10 and maintained at 1/10-2/3 of the total OFC doses; and 3) underwent OFCs after one year. We evaluated adverse events during low dose OIT and changes in tolerated OFC doses from initiation to 1 year. RESULTS: Seventeen patients aged 1-9 years (10, egg; 7, milk; with duplication) were analyzed. Regarding adverse events, symptoms involving the oral cavity occurred with 11/17 cases, and systemic symptoms occurred 0.7 times/cases/year. Median (interquartile range; IQR) total tolerated OFC doses increased from 0.3 (0.3-1.0) to 3.0 g or ml (1.0-3.0) (p50.002). Median (IQR) ovomucoid-sIgE and milk-sIgE tended to decrease from 48.0 (33.8-64.2) to 29.1 UA/mL (17.0-39.4) (p50.20), 69.7 (48.6-100.0) to 24.2 UA/mL (17.8-100.0) (p50.36), respectively. CONCLUSIONS: Adverse events occurred 0.7 times/cases/year. It might be necessary to implement lower doses in our protocol.
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Clinical utility of serum specific IgE food testing in general practice: A tertiary care experience Ejaz Yousef, MD FAAAAI; Nemours Children' Clinic, Jacksonville, FL and Michael Schrum, NSU, Fort Lauderdale, FL. RATIONALE: Serum Specific IgE (SSIgE) testing is the preferred method for diagnosis of food allergy by Primary Care Physicians(PCPs). However, the diagnostic value of such tests, without a valid history, is questionable due to high false positive results. We tested the hypothesis that greater than 50% of positive food allergens according to Serum Specific Immunoassays do not correlate with a definitive food allergy. METHODS: We performed a medical record review on 336 patients previously diagnosed with ''food allergies'' based on positive SSIgE ordered by PCPs. We compared these SSIgE results with an assessment from our tertiary care center Allergy specialists which included detailed history, skin prick testing and home/in office oral challenges. RESULTS: The top 10 foods tested by PCPs were milk, peanut, wheat, shrimp, soybean, codfish, walnut, egg, sesame, and scallop. 167 (49.7%) subjects had positive skin testing to one or more foods. Only 41(12.20%) had positive oral food challenges. Average total serum IgE per patient was 581IU/ml (ref: 100-300IU/ml). SSIgE assay was obtained only on 71 subjects in 2008 compared to 240 in 2018. CONCLUSIONS: False positive rate in our study is >80 % compared to >50% in the previous studies.A high average total serum IgE level/ patient related to nonspecific IgE and cross-reactive but clinically irrelevant allergen SSIgE might be a reason for false-positive IgE values for the specific food allergen.A rising trend for indiscriminate ordering of SSIgE in the last 10 years has caused not only the over diagnosis of food allergy but also an unnecessary cost of evaluation. The initial 270 patients have been reported. Based on our and others' experience we have adjusted treatment age and the POIT process in an effort to increase the availability of POIT and improve the outcome. We contrast the outcomes of the initial and subsequently treated patients. METHODS: Retrospective record review of patients receiving POIT approved by the North Texas IRB. POIT was administered according to modifications of previously reported protocols. RESULTS: 99% of the initial patients and 50% of the recent patients were >5yo. 82% of the initial patients (excluding 8 [2.9%] who transferred care) and 94% of the subsequent 67 patients reached their target peanut protein dose (TPPD). Epinephrine treated reactions occurred in 24% of the initial but only 7.5% of the subsequently treated patients. 14% of the initially treated patients but only 7.5% of the recent patients experienced eosinophilic esophagitis-like OIT-related GI symptoms. Among the recently treated patients there was no significant difference in adverse events between those <5yo and >5yo. CONCLUSIONS: Changes in POIT protocols and management experience from treating >325 patients has increased the likelihood of desensitization and decreased the rate of serious GI and systemic adverse events requiring epinephrine. These improvements cannot be explained by the inclusion of younger patients.
